ArticleJournal of diabetes investigation2025
Leptin promoter G2548A variant, elevated plasma leptin levels, and increased risk of Type 2 diabetes with CAD in Iranian patients: A genetic association study.
Article in Journal of diabetes investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Considerations on mechanistic coherence and generalizability in the study of leptin G2548A variant and T2DM with CAD.Journal of diabetes investigation · 2026Article
- Association Between Frailty and Leptin Levels in Patients with Stable Coronary Artery Disease.Diagnostics (Basel, Switzerland) · 2026Article
- Leptin-Independent Association Between SNVs in the Leptin Gene and HDL-C and Apo-AI in Children.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundType 2 diabetes mellitus (T2DM) is a significant risk factor for coronary artery disease (CAD). Leptin polymorphism is known to be associated with obesity and Type 2 diabetes mellitus. This study aimed to investigate the possible links between a specific leptin polymorphism (LEP 2548G/A) and plasma leptin level with the risk of Type 2 diabetes mellitus patients with CAD in the Iranian population for the first time. METHODS AND
resultsA total of 150 patients with Type 2 diabetes mellitus and CAD were included in the study, along with 150 nondiabetic controls. Blood samples were collected from participants. Biochemical analysis and genotyping were done using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. The plasma leptin level was higher in females in the case group. There was a positive correlation between females and obese diabetic subjects (P < 0.001). Regarding the single-nucleotide polymorphism in the leptin gene promoter, we found that the variant genotypes AA and GG were associated with a twofold (OR = 2.09, P = 0.006) and fourfold (OR = 4.2, P = 0.017) increased risk of Type 2 diabetes mellitus patients with CAD, respectively. The GG genotype was also associated with obesity and higher plasma leptin level in the case group (OR = 4.92, P < 0.001).
conclusionsLeptin G2548A and plasma leptin levels may contribute to Type 2 diabetes with CAD in the Iranian population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.